Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cetirizine hydrochloride is a second-generation, selective histamine H1-receptor antagonist used to relieve symptoms of allergic rhinitis (hay fever), perennial allergies, and chronic urticaria (hives). It works by blocking the action of histamine at the H1 receptor sites on respiratory smooth muscle cells, vascular endothelial cells, immune cells, and in the gastrointestinal tract. This reduces sneezing, itching, watery eyes, runny nose, and hives. Unlike first-generation antihistamines such as diphenhydramine or doxylamine, cetirizine crosses the blood-brain barrier minimally and therefore causes less sedation. It also exhibits anti-inflammatory activity by reducing infiltration of inflammatory cells in allergic conditions.[1][2][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cetirizine hydrochloride.